InvestorsHub Logo

SSP

Followers 642
Posts 44673
Boards Moderated 3
Alias Born 08/02/2000

SSP

Member Level

Re: ottoman post# 270616

Tuesday, 03/21/2017 11:54:12 AM

Tuesday, March 21, 2017 11:54:12 AM

Post# of 285870
PTIE - problem is, FDA only gave guidelines so they can resubmit. The real play is when they get acceptance on the submit, since this would mean more chance they approve the drug.

"In recent weeks we have worked closely with the FDA, said Remi Barbier, President & CEO. We appreciate their guidance, we understand their new requirements and we believe were now on track to make expeditious progress toward a resubmission of the REMOXY NDA."

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.